Defining the Investigator’s Role in Sample Custody and Ensuring CAPA-Based Compliance

Introduction: Sample Custody Responsibilities at the Site Level

In a clinical trial, while the sponsor retains overall responsibility for study conduct, investigators play a pivotal role in safeguarding the integrity of biological samples collected at their sites. The accurate tracking, documentation, and transfer of these samples directly impact the validity of trial data. Any deviation in the sample custody chain can raise concerns about Good Clinical Practice (GCP) compliance, data integrity, and subject safety.

Regulatory inspections across the globe have repeatedly flagged the lack of clear site-level ownership of sample custody procedures. This article outlines the expectations set by regulatory authorities such as the FDA, EMA, and ICH for investigator involvement in sample custody. It also presents real-world case studies of compliance failures and the CAPA measures that were implemented to restore compliance and inspection readiness.

Regulatory Expectations for Investigator Oversight in Sample Custody

Several global guidelines emphasize that investigators must ensure proper custody and documentation of clinical samples:

• ICH E6(R2) GCP: Investigators are responsible for ensuring that trial-related duties are delegated appropriately and documented clearly. This includes sample handling and custody.
• FDA 21 CFR Part 312.60: Investigators must ensure that the study is conducted according to the investigational plan and applicable regulations, which includes the custody of specimens.
• EMA GCP Inspectors Working Group: The PI is accountable for ensuring that samples are collected, labeled, stored, and transferred in a manner consistent with the trial protocol and ALCOA principles.

Failure to comply with these expectations may result in inspection findings, data exclusion, or sponsor-initiated site closure.

Case Study 1: Custody Delegation Without Documentation

In a cardiovascular study conducted across multiple EU sites, an EMA inspection revealed that several sample custody tasks, such as transfer from clinic to lab freezer, were performed by unlisted site staff. These individuals were not documented in the delegation log and had received no training in GCP or sample handling SOPs.

Root Cause: Informal delegation practices at busy hospital-based sites.

CAPA Actions:

• Updated the delegation log template to include sample custody roles explicitly.
• Conducted a site-wide training on GCP and sample handling SOPs.
• Introduced electronic custody logs with time-stamped entries by authorized personnel only.

Sample Investigator Responsibilities in the Custody Lifecycle

Investigators are responsible for implementing and overseeing the following custody-related tasks:

• Supervision of sample collection in line with protocol requirements
• Verification that proper labeling, coding, and blinding procedures are followed
• Ensuring secure, validated storage conditions are maintained at site
• Review and sign-off of custody logs, especially during handovers to couriers
• Immediate documentation and escalation of custody deviations
• Training of delegated staff on SOPs and documentation practices

Case Study 2: Missing Investigator Oversight on Sample Reconciliation

During a U.S.-based oncology trial, a CRO discovered during interim monitoring that several blood samples were marked “shipped” in the eCRF, but were not received at the central lab. Upon investigation, it was found that site staff had failed to reconcile the shipment manifest before dispatching samples.

Root Cause: Investigator oversight lapse in final shipment validation.

CAPA Actions:

• Developed a “PI Review Checklist” for all outbound sample shipments.
• Modified site SOPs to include mandatory reconciliation before dispatch.
• Trained all site investigators on sample shipment validation protocols.

CAPA Framework for Investigator-Linked Custody Deviations

Field Practices: Central Lab and Investigator Collaboration

Investigators must also coordinate with laboratories to ensure smooth sample transition. In a case where mislabeled samples arrived at the central lab, a Canadian sponsor determined that the site PI had not verified labels during oversight rounds.

This led to confusion in matching samples to subjects, causing data delays. The site adopted a co-signed sample log (by lab and PI) to ensure label accuracy at point of shipment.

Best Practices for Training Investigators on Sample Custody

• Annual mandatory refresher training on GCP and sample SOPs
• Site initiation visits must include custody and deviation logging expectations
• Monitors should document PI compliance with custody expectations during site visits
• Custody audits to be part of periodic site quality assessments

External Reference

For further reading on the investigator’s responsibilities in clinical operations, consult the ISRCTN Registry for protocol and documentation standards.

Conclusion

Investigators are the custodians of both patient safety and scientific integrity at their sites. Their role in the custody of clinical samples is not merely operational—it is regulatory. Ensuring that investigators are well-versed in their responsibilities and equipped with the right training, documentation tools, and oversight procedures is essential to inspection readiness and data quality. Through proactive CAPA frameworks, sponsors can reinforce a culture of compliance that aligns with global regulatory expectations.

Ensuring Chain of Custody in Clinical Trial Logistics

Introduction: Why Chain of Custody Matters

Chain of custody (CoC) refers to the documented and unbroken trail showing the movement and handling of investigational medicinal products (IMPs) from manufacturer to depot, site, and ultimately the patient. For US sponsors, the FDA requires that every transfer of custody is recorded, ensuring accountability, product integrity, and patient safety. Inadequate custody documentation can result in Form 483s, warning letters, and, in some cases, trial suspension.

Data from the EU Clinical Trials Register highlights that nearly 18% of logistics-related findings during inspections were due to incomplete custody records. With increasingly global and decentralized trials, ensuring an unbroken chain of custody has become both more difficult and more important.

Regulatory Expectations for Chain of Custody

Regulatory frameworks require full accountability across custody transfers:

• FDA 21 CFR Part 312.57: Sponsors must maintain detailed shipment, transfer, and disposition records for IMPs.
• FDA 21 CFR Part 211: Requires control systems to ensure IMPs are stored and distributed in accordance with labeled conditions.
• ICH E6(R3): Requires investigators and sponsors to ensure accountability of IMPs at every stage, including custody transfers.
• EMA GDP: Mandates documentation of custody handovers, courier compliance, and storage conditions.

WHO further emphasizes that chain of custody safeguards protect against counterfeit or diverted products in vulnerable supply chains. Regulators expect documented evidence that no custody gap exists throughout the trial lifecycle.

Audit Findings in Custody Oversight

FDA and sponsor audits frequently cite deficiencies in custody management:

Example: In a Phase III oncology trial, FDA inspectors identified missing handover signatures in courier logs. The sponsor received a critical observation for inadequate chain-of-custody documentation.

Root Causes of Custody Oversight Failures

Root cause analysis often identifies:

• Absence of standardized custody SOPs across depots, couriers, and sites.
• Over-reliance on paper logs prone to transcription and loss.
• Insufficient sponsor oversight of courier and depot custody practices.
• Untrained staff at sites failing to maintain custody documentation.

Case Example: In a vaccine trial, custody gaps were identified between depot release and site receipt. Investigation showed couriers were subcontracting deliveries without sponsor authorization, resulting in missing custody records.

Corrective and Preventive Actions (CAPA) for Chain of Custody

To meet FDA and EMA expectations, sponsors must embed CAPA into custody oversight:

1. Immediate Correction: Reconcile custody records, quarantine affected IMPs, and retrain staff involved.
2. Root Cause Analysis: Identify systemic issues such as missing SOPs, inadequate vendor oversight, or poor training.
3. Corrective Actions: Revise SOPs, implement electronic custody systems, and qualify vendors.
4. Preventive Actions: Conduct annual audits, enforce contractual clauses on custody, and integrate custody logs into eTMF systems.

Example: A US sponsor implemented electronic custody tracking linked with GPS-enabled courier systems. This reduced missing custody logs by 95% and improved FDA inspection outcomes.

Best Practices in Custody Oversight

To ensure compliance, US sponsors should adopt the following practices:

• Develop SOPs covering all custody transfers, including depots, couriers, and sites.
• Use electronic custody systems with audit trails and automated reconciliation.
• Qualify couriers and depots through GDP-focused audits.
• Train site and depot staff on custody documentation requirements.
• Archive custody records in the Trial Master File (TMF).

KPIs for custody oversight:

Case Studies of Custody Deficiencies

Case 1: FDA cited a sponsor in a cardiovascular trial for custody gaps between depot and site records.
Case 2: EMA inspection identified missing courier custody logs in a rare disease trial.
Case 3: WHO audit observed lack of custody SOPs in a multi-country vaccine program, raising risks of diversion.

Conclusion: Treating Custody as a Compliance Imperative

Chain of custody is not a clerical exercise—it is a compliance-critical requirement. For US sponsors, FDA expects full custody documentation, reconciliation, and vendor oversight. By embedding CAPA, digitizing custody records, and qualifying vendors, sponsors can ensure inspection readiness and protect patient safety.

Sponsors that treat custody oversight as a strategic compliance function not only reduce audit findings but also strengthen trust in trial data and regulatory submissions.